Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Public ClinicalTrials.gov record NCT00292396. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Subcutaneous Injections of ABT-874 vs. Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis.
Study identification
- NCT ID
- NCT00292396
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2005
- Primary completion
- Mar 31, 2008
- Completion
- Mar 31, 2008
- Last update posted
- Jan 17, 2013
2005 – 2008
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 3351 | San Diego | California | 92123 | — |
| Site Reference ID/Investigator# 3347 | Alpharetta | Georgia | 30022 | — |
| Site Reference ID/Investigator# 3348 | Skokie | Illinois | 60077 | — |
| Site Reference ID/Investigator# 993 | Indianapolis | Indiana | 46256 | — |
| Site Reference ID/Investigator# 990 | Boston | Massachusetts | 02114 | — |
| Site Reference ID/Investigator# 3349 | St Louis | Missouri | 63117 | — |
| Site Reference ID/Investigator# 992 | Cincinnati | Ohio | 45219 | — |
| Site Reference ID/Investigator# 991 | Lake Oswego | Oregon | 97035 | — |
| Site Reference ID/Investigator# 3367 | Portland | Oregon | 97223 | — |
| Site Reference ID/Investigator# 3346 | Johnston | Rhode Island | 02919 | — |
| Site Reference ID/Investigator# 994 | Nashville | Tennessee | 37215 | — |
| Site Reference ID/Investigator# 3350 | Dallas | Texas | 75246-1613 | — |
| Site Reference ID/Investigator# 796 | Houston | Texas | 77030 | — |
| Site Reference ID/Investigator# 2081 | Salt Lake City | Utah | 84132 | — |
| Site Reference ID/Investigator# 3366 | Norfolk | Virginia | 23507 | — |
| Site Reference ID/Investigator# 989 | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00292396, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 17, 2013 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00292396 live on ClinicalTrials.gov.